Maplight - An experimental drug to moderate behavioural symptoms in people with autism

A clinical trial to investigate the efficacy, safety and tolerability of ML-004 for treatment of the core behavioural symptoms in Autistic people

Autism

The study evaluates the safety, efficacy and tolerability of investigational drug ML-004, compared to placebo, for treatment of the core symptoms in Autistic people.  The study will determine whether treatment with ML-004 results in improved social communication, as well as other aspects of autism.

Category
Trial Status
Recruiting
Trial Phase
Phase 0
Trial contact details
Contact Person
Delphine Lévy-Bencheton
What you need to know

Who can take part?

Participants must:

  • be aged 15 to 45 years and diagnosed with Autism Spectrum Disorder
  • not be currently taking most psychotropic medications, including SSRI and SNRI antidepressants.
  • have a reasonable degree of social difficulties
  • have someone who lives with them or knows them very well who can attend appointments and complete questionnaires.
  • be able to reliably swallow oral pills
  • must avoid pregnancy during the study if the participant is of childbearing potential

What is involved for you?

The study treatment is a tablet taken once daily by mouth, which contains either the compound ML-004 or placebo. ML-004 has been available as a migraine treatment for several years.

The study investigations include:

  • Questionnaires for the participant and support person
  • Physical examination and vital signs
  • Electrocardiogram (ECG)
  • Video eye-tracking tests
  • Blood tests
  • Urine tests

All research clinical trials news

A new diagnostic and treatment approach for bladder cancer will undergo a clinical trial in Queensland.

07

May

Technology shines a light on better bladder cancer detection

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Displaying results 1-3 (of 19)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|